At Long Last, Inflammatory Hypothesis Confirmed in CVD

https://www.medpagetoday.com/MeetingCoverage/ESC/67529?xid=nl_mpt_DHE_2017-08-28&eun=g721819d0r&pos=0 Long-awaited evidence that targeting an inflammatory pathway can reduce heart attacks and stroke independent of lipids is now in hand -- canakinumab (Ilaris) reduced events by 15% compared with placebo. But there is a two-fold catch: Because canakinumab is an immunotherapy, the drug carries a high price tag and use was associated with an increased risk of fatal infections.